Anti-cancer drug clinical research

Abstract Malignant tumors are major diseases that seriously threaten human health, and the unmet clinical demand for treatments in the field of oncology has been persistently large. The research and development of new antineoplastic drugs has become a powerful means to address this demand. The purpose of this guideline is to provide a systematic overview and summary of clinical research on antineoplastic drugs in terms of study format, trial staging, mechanism of action, ethical review, trial process, patient needs, and the evaluation of efficacy and adverse events. It provides practical suggestions and references to aid the fundamental role of clinical research on antineoplastic drugs, i.e., to address clinical needs and maximize patient benefits.

Authors

Institutions

Publication Details

Journal
Holistic Integrative Oncology
Published
2026-09-04
DOI
https://doi.org/10.1007/s44178-026-00289-2
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Anti-cancer drug clinical research

Jinfei Chen, Fei Ma, Chunxia Su, Caicun Zhou et al.
Holistic Integrative Oncology
Advanced Breast Cancer Therapies
article

Anti-cancer drug clinical research

Jinfei Chen, Fei Ma, Chunxia Su, Caicun Zhou, Zhehai Wang, Yongmei Yin, Kangsheng Gu, Xichun Hu, Jingxun Wu, Jianhua Chang, Hongyun Zhao, Zhao Yan, Yanhong Deng, Jiayu Wang, Li Zhang, Qitao Yu, Yi Ba, Dongsheng Zhang, Binghe Xu, Jian Li, Tianshu Liu, Hongming Pan, Wenbin Li, Yanqiao Zhang, Yunpeng Liu, Lin Shen, Jianping Xiong
article en

Abstract

Abstract Malignant tumors are major diseases that seriously threaten human health, and the unmet clinical demand for treatments in the field of oncology has been persistently large. The research and development of new antineoplastic drugs has become a powerful means to address this demand. The purpose of this guideline is to provide a systematic overview and summary of clinical research on antineoplastic drugs in terms of study format, trial staging, mechanism of action, ethical review, trial process, patient needs, and the evaluation of efficacy and adverse events. It provides practical suggestions and references to aid the fundamental role of clinical research on antineoplastic drugs, i.e., to address clinical needs and maximize patient benefits.

Holistic Integrative OncologyVol. 5(1)
Nanchang University (CN), Harbin Medical University (CN), Sun Yat-sen University (CN), Anhui Medical University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Peking Union Medical College Hospital (CN), Sir Run Run Shaw Hospital (CN), First Affiliated Hospital of Xiamen University (CN), Beijing Tian Tan Hospital (CN), Fudan University Shanghai Cancer Center (CN), Sixth Affiliated Hospital of Sun Yat-sen University (CN), Peking University Cancer Hospital (CN), Shandong Tumor Hospital (CN), Third Affiliated Hospital of Harbin Medical University (CN), Zhongshan Hospital (CN), Shanghai Pulmonary Hospital (CN), Shanghai East Hospital (CN), First Affiliated Hospital of Anhui Medical University (CN), First Hospital of China Medical University (CN), Sun Yat-sen University Cancer Center (CN), Jiangsu Province Hospital (CN), Tumor Hospital of Guangxi Medical University (CN), Chinese Anti-Cancer Association (CN), Shandong First Medical University (CN), First Affiliated Hospital of Nanchang University (CN), China Medical University (CN)
Good health and well-being
Openalex Percentile: Top 11%
Advanced Breast Cancer Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.